Afamelanotide is a MC1R agonist. It is filed in this library under skin & aging, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.
Regulatory status
Afamelanotide has an FDA-approved product on the U.S. market, marketed as Scenesse under application NDA210797.
The current label is held by Clinuvel Inc.
From the FDA label
SCENESSE ® is indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP).Quoted from the FDA-approved prescribing information
The evidence
3 sources on Afamelanotide published between 2015 and 2023, each resolved to its journal of record. Titles are listed so you can judge the evidence rather than take a summary on trust.
Nearby
A 60-second questionnaire, reviewed by a U.S.-licensed physician.
Find my protocolEducational reference only. This page explains what has been published about Afamelanotide. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.
Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.
All 150 peptides